The uncertainty around tariffs and trade production measures has muted economic growth. President Trump has once again ...

Taiho Pharmaceutical’s investigational Duchenne muscular dystrophy (DMD) therapy, pizuglanstat, has shown no benefit in a Phase III trial.

Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...

Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy ...

AGAMREE, which is already approved and available in the United States, could become the first authorized DMD treatment in Canada if approved.

If approved, AGAMREE ® would be the first and only therapy approved by Health Canada with an indication for the treatment of Duchenne muscular dystrophy (DMD). Health Canada has granted AGAMREE ® a ...

Santhera Pharmaceuticals, a specialty pharmaceutical company focused on rare diseases, announces an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the ...

About AGAMREE® (vamorolone) AGAMREE is a novel drug with a mode of action based on binding to the same receptor as glucocorticoids but modifying its downstream activity. Moreover, it is not a ...

Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarter Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that ...